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Bringing high-grade arteriovenous malformations under 
control: clinical outcomes following multimodality 
treatment in children
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OBJECTIVE Brain arteriovenous malformations (AVMs) consist of dysplastic blood vessels with direct arteriovenous 
shunts that can hemorrhage spontaneously. In children, a higher lifetime hemorrhage risk must be balanced with 
treatment-related morbidity. The authors describe a collaborative, multimodal strategy resulting in effective and safe 
treatment of pediatric AVMs.
METHODS A retrospective analysis of a prospectively maintained database was performed in children with treated and 
nontreated pediatric AVMs at the University of California, San Francisco, from 1998 to 2017. Inclusion criteria were age 
≤ 18 years at time of diagnosis and an AVM confirmed by a catheter angiogram.
RESULTS The authors evaluated 189 pediatric patients with AVMs over the study period, including 119 ruptured (63%) 
and 70 unruptured (37%) AVMs. The mean age at diagnosis was 11.6 ± 4.3 years. With respect to Spetzler-Martin (SM) 
grade, there were 38 (20.1%) grade I, 40 (21.2%) grade II, 62 (32.8%) grade III, 40 (21.2%) grade IV, and 9 (4.8%) grade 
V lesions. Six patients were managed conservatively, and 183 patients underwent treatment, including 120 resections, 
82 stereotactic radiosurgery (SRS), and 37 endovascular embolizations. Forty-four of 49 (89.8%) high-grade AVMs (SM 
grade IV or V) were treated. Multiple treatment modalities were used in 29.5% of low-grade and 27.3% of high-grade 
AVMs. Complete angiographic obliteration was obtained in 73.4% of low-grade lesions (SM grade I–III) and in 45.2% of 
high-grade lesions. A periprocedural stroke occurred in a single patient (0.5%), and there was 1 treatment-related death. 
The mean clinical follow-up for the cohort was 4.1 ± 4.6 years, and 96.6% and 84.3% of patients neurologically improved 
or remained unchanged in the ruptured and unruptured AVM groups following treatment, respectively. There were 16 
bleeding events following initiation of AVM treatment (annual rate: 0.02 events per person-year).
CONCLUSIONS Coordinated multidisciplinary evaluation and individualized planning can result in safe and effective 
treatment of children with AVMs. In particular, it is possible to treat the majority of high-grade AVMs with an acceptable 
safety profile. Judicious use of multimodality therapy should be limited to appropriately selected patients after thorough 
team-based discussions to avoid additive morbidity. Future multicenter studies are required to better design predictive 
models to aid with patient selection for multimodal pediatric care, especially with high-grade AVMs.
https://thejns.org/doi/abs/10.3171/2020.1.PEDS19487
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Brain arteriovenous malformations (AVMs) are dysplastic, fragile clusters of blood vessels formed by abnormal connections between arteries and 
veins leading to vascular shunting, which can cause spon-
taneous intracerebral hemorrhages. AVMs are the leading 
cause of nontraumatic intracerebral hemorrhage in chil-
dren and account for 30%–50% of all spontaneous hemor-
rhages.1–3 Brain hemorrhage is associated with a mortality 
rate of 25%,4 and recent studies in children have estimated 
the annual hemorrhage rate to range between 0.9% and 
6.3%.1,3 When diagnosed in childhood or adolescence, 
the annualized hemorrhage risk over a greater number of 
expected years to live in comparison with adults leads to 
a high cumulative lifetime hemorrhage risk. Intervention 
to achieve AVM obliteration is therefore often favored to 
mitigate the potential morbidity of future hemorrhage.
Numerous pediatric case series have reported compli-
cation and obliteration rates associated with various treat-
ment modalities, including microsurgical resection,3,5–7 
embolization,8,9 and stereotactic radiosurgery (SRS).10–12 
However, randomized controlled trials and prospective 
registries, such as A Randomized Trial of Unruptured 
Brain AVMs (ARUBA) and the Scottish Audit of Intra-
cranial Vascular Malformations (SAIVM), excluded pe-
diatric patients,13,14 and selection of optimal treatment 
strategies, especially with unruptured AVMs or AVMs 
with higher clinical Spetzler-Martin (SM) grades, remains 
controversial.
Traditionally, many high-grade AVMs have been con-
sidered largely untreatable. Combined strategies with mul-
tiple treatment modalities may allow higher-grade AVMs 
to be treated, and institutions have reported outcomes with 
multimodality treatments.3,6, 15,16 However, multimodality 
treatment has been associated with increased morbidity, 
especially when targeting high-grade AVMs. Here, we 
report our 20-year institutional experience using a mul-
timodal, interdisciplinary approach for the management 
of children with ruptured and unruptured AVMs, with an 
emphasis on those with higher grades (SM grade IV or V).
Methods
Patient Population
A prospectively maintained database of all patients 
with AVMs evaluated at the University of California, San 
Francisco, from June 1998 to January 2017 was reviewed 
to identify pediatric patients (defined as age ≤ 18 years) at 
initial clinical presentation, with either ruptured or unrup-
tured brain AVMs. Patients were included in this analy-
sis regardless of modality of management. Patients with 
multiple brain AVMs or other vascular malformations, 
including cavernous malformations, vein of Galen mal-
formations, dural arteriovenous fistulas, or spinal vascular 
malformations, were excluded from analysis. We obtained 
informed consent and assent, when appropriate, prior to 
including patients in the database. Prior to data collection, 
institutional review board approval was obtained from the 
University of California, San Francisco.
Clinical Decision-Making and Treatment Strategy
Each patient was thoroughly evaluated by a multidis-
ciplinary team, which included pediatric vascular neu-
rologists, cerebrovascular neurosurgeons, pediatric neu-
rosurgeons, neurointerventional radiologists, and radia-
tion oncologists. For patients who were clinically stable, 
imaging was reviewed at a weekly vascular conference 
with all specialties represented to discuss the optimal 
treatment. For patients requiring emergency intervention, 
discussions regarding AVM management were expedited 
and coordinated through the pediatric vascular neurol-
ogy service. In general, treatment decision-making was 
guided by the rupture status, Lawton-Young supplemen-
tary grading scale (Supp-SM),17,18 surgical accessibility of 
the lesion, and the presence of high-risk features, such as 
flow-related or intranidal aneurysms or enlarging venous 
varices (Fig. 1).
The surgical and SRS approaches used at our insti-
tution for the treatment of pediatric AVMs have been 
previously described.7,11,19 AVMs treated with SRS were 
restaged 3 years after initial treatment with digital sub-
traction angiography (DSA) to determine the potential for 
resection or further SRS. Endovascular embolization was 
performed with ethylene vinyl copolymer (Onyx), N-butyl 
cyanoacrylate (NBCA) glue, or detachable coils. In se-
lect cases, the AVM was too diffuse (e.g., involvement of 
the entire cerebral hemisphere) to be safely treated and/
or the family chose conservative management with serial 
imaging every 5 years unless new neurological symptoms 
developed.
Data Collection
Prospective collection of patient demographic informa-
tion, clinical presentation, postprocedural neurological 
deficits and complications, hemorrhagic events, and func-
tional status as measured by the modified Rankin Scale 
(mRS) was validated through retrospective review of the 
medical record. SM grade and Supp-SM score were as-
signed based on evaluation of DSA.17,18,20 Lesion location 
was defined through review of preintervention MR angi-
ography or CT angiography.19
Definitions
Arterial ischemic stroke was defined clinically by a fo-
cal neurological deficit corresponding to the territory of 
a major cerebral artery that persisted for > 24 hours and, 
when available, confirmed on MRI. Radiographic oblit-
eration was defined as no evidence of residual AVM on 
postprocedural DSA. We define mRS scores of 0–2 and ≥ 
3 as good and poor outcomes, respectively.5–7,11
Statistical Analysis
We performed descriptive analyses, calculating means 
and standard deviations for continuous variables and pro-
portions for categorical variables. Pearson’s chi-square 
test and ANOVA were used to assess between-group 
differences. A Cochran-Armitage trend test was used to 
evaluate the hypothesized relationship between clinical 
or radiographic variables with posttreatment hemorrhage 
or radiographic obliteration. All statistical analyses were 
performed using R version 3.5.2 (http://cran.r-project.
org/).
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FIG. 1. Current approach to treatment planning for pediatric brain AVMs at the University of California, San Francisco. The 
decision-making algorithm is shown, which broadly guides allocation of different treatment modalities, including resection, SRS, 
and endovascular embolization. Each case is discussed extensively through multidisciplinary teams comprising pediatric neuro-
surgeons, dual-trained cerebrovascular neurosurgeons, pediatric vascular neurologists, neurointerventional radiologists, radiation 
oncologists, and pediatricians. Treatment plans are individualized on the basis of patient, radiographic, and/or clinical nuances 
and in accordance with the family’s wishes. A patient older than 5 years is considered a candidate for SRS with an acceptable 
neurological prognosis (life expectancy of > 5–10 years). inc. = including; VS = volume-staged; yo = years old.
Winkler et al. 
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Results
Patient Demographics and AVM Characteristics
From 1998 until 2017, 189 pediatric patients with brain 
AVMs were evaluated at the University of California, San 
Francisco. Eight patients with multiple AVMs were ex-
cluded from this analysis. Patient demographic and clinical 
variables, and distribution of AVM locations are included 
in Table 1. In total, 119 of 189 (63%) AVMs presented 
with spontaneous hemorrhage (defined as “ruptured”). For 
unruptured AVMs, 87.1% of patients had symptoms that 
included seizures (47.1%), headaches (44.3%), and focal 
neurological deficits (41.4%).
Treatment of AVMs
The various modalities used to treat patients in this 
cohort are described in Table 2. Five of 6 patients who 
were medically managed had high-grade (SM grade IV 
or V) AVMs. Figure 1 provides our current general de-
cision algorithm used at our institution. Ruptured AVMs 
were more likely to be treated with resection (p = 0.03), 
and there was a trend toward treating unruptured AVMs 
with SRS (p = 0.06) (Table 2). Patients with AVMs that 
were cortical only, cortical/subcortical, and subcortical 
only were treated with surgery (72.9%, 55.0%, and 39.3%, 
respectively) and with SRS (36.5%, 50.0%, and 71.4%, re-
spectively).
Ruptured AVMs
Of the entire cohort (n = 189), 119 (63.0%) presented 
with spontaneous intracerebral hemorrhage; of these pa-
tients, 117 underwent treatment (98.3%). The median time 
from diagnosis to treatment was 14 days (range 0–8.8 
years). The median number of therapeutic interventions 
was 1 (range 1–4). Complete obliteration was seen in 86 
cases (72.2%) across treatment modalities, with an aver-
age of 1.6 treatments required to achieve complete oblit-
eration. Eighteen patients (15.1%) required emergency de-
compressive hemicraniectomy; many of these procedures 
were performed at outside facilities. In these patients, 
subsequent treatment of the AVM was performed with a 
mean latency of 18.6 ± 6.8 days. No rehemorrhage events 
were reported following surgical decompression prior to 
more definitive therapy.
Resection with or without embolization or radiosur-
gery was performed for 84 ruptured AVMs (70.6%). 
Stratified by SM grade, resection was performed in 24 
of 27 (88.9%) grade I, 19 of 24 (79.2%) grade II, 25 of 41 
(61%) grade III, and 16 of 25 (64.0%) grade IV. No surgi-
cal procedures were performed in patients with SM grade 
V AVMs. Preoperative embolization was performed in 
15 patients (17.8%). Five (6.0%) and 8 (9.5%) patients re-
quired a second surgical procedure or radiosurgical treat-
ment after the initial resection, respectively, for residual 
shunting on postoperative DSA. Preoperative volume-
staged SRS was performed in 7 patients (5.9%) with rup-
tured AVMs to facilitate delayed resection. Embolization 
as the sole treatment was performed in 2 patients (1.7%), 
and 29 patients (24.4%) underwent one or more treat-
ments with SRS alone.
Unruptured AVMs
Seventy AVMs (37%) were unruptured on initial pre-
sentation, and 66 patients (94%) underwent treatment. 
The median time from diagnosis to treatment was 60.5 
days (range 0–5.7 years). The median number of thera-
peutic interventions was 1 (range 1–6). In the latency pe-
riod between diagnosis and treatment, there was a single 
bleeding event in a patient with an SM grade V AVM 
while awaiting SRS. For treated AVMs, complete oblit-
TABLE 1. Demographics and clinical characteristics of pediatric 
brain AVMs
Ruptured (n 
= 119)
Unruptured 
(n = 70)
Total (n = 
189)
p 
Value*
Demographics
 Mean age, yrs 11.6 ± 4.3 12.9 ± 4.7 12.1 ± 4.3 <0.01
 Sex
  Male 66 (55.5) 37 (52.9) 103 (54.5) 0.84
  Female 53 (44.5) 33 (47.1) 86 (45.5)
AVM grading
 SM grade
  I 27 (22.7) 11 (15.7) 38 (20.1) 0.33
  II 24 (20.2) 16 (22.9) 40 (21.2) 0.98
  III 41 (34.5) 21 (30.0) 62 (32.8) 0.50
  IV 25 (21.0) 15 (21.4) 40 (21.2) 0.48
  V 2 (1.7) 7 (10.0) 9 (4.8) 0.06
 Supp-SM score†  
  1 74 (62.2) 0 (0) 74 (39.2)
  2 45 (37.8) 42 (60.0) 87 (46.0)
  3 0 (0) 28 (40.0) 28 (14.8)
Size of nidus, cm 2.55 ± 1.67 3.63 ± 1.52 2.95 ± 1.67 <0.01
Noncompact nidus 
(diffuse)
45 (37.8) 28 (40) 73 (38.6) 0.89
Eloquence 67 (56.3) 38 (54.3) 105 (55.6) 0.91
Deep venous  
drainage
77 (64.7) 39 (55.7) 116 (61.4) 0.28
Laterality
 Rt 49 (41.2) 39 (55.7) 88 (46.6) 0.07
 Lt 67 (56.3) 31 (44.3) 98 (51.9) 0.15
 Midline 3 (2.52) 0 (0) 3 (1.6) 0.46
AVM location
 Frontal 26 (21.8) 23 (32.9) 49 (25.9) 0.06
 Parietooccipital 21 (17.6) 24 (34.3) 45 (23.8) 0.02
 Temporal 17 (14.3) 6 (8.6) 23 (12.2) 0.35
 Cerebellar 13 (10.9) 7 (10) 20 (10.6) 0.99
 Deep 24 (20.2) 6 (8.6) 30 (15.9) 0.06
 Ventricular/ 
 periventricular
15 (12.6) 2 (2.9) 17 (9.0) 0.05
 Brainstem 3 (2.52) 2 (2.9) 5 (2.6) 0.99
Values are presented as number (%). Boldface type indicates statistical 
significance.
* Comparison between ruptured and unruptured aneurysms.
† The Supp-SM scale ranges from 1 to 3 in pediatric patients.
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eration was seen in 36 cases (54.5%) across treatment 
modalities, with an average of 1.95 treatments to achieve 
complete obliteration.
Resection with or without embolization or SRS was 
performed in 36 of 70 (51.4%) unruptured AVMs. The 
mean time to surgery for unruptured lesions was 57 days. 
Stratified by SM grade, resection was performed in 10 
of 11 (90.9%) grade I, 8 of 16 (50.0%) grade II, 14 of 21 
(66.7%) grade III, 3 of 15 (20.0%) grade IV, and 1 of 7 
(14.3%) grade V AVMs. Preoperative embolization was 
performed in 12 patients (33.3%). Four patients (11.1%) re-
quired repeat surgery for residual shunting. Preoperative 
volume-staged SRS was performed in 5 patients (7.1%). 
Postoperative SRS was performed in 1 case (1.6%). Em-
bolization as the sole treatment was performed in 3 cases 
(4.3%). Twenty-seven patients underwent one or more 
treatments with SRS alone (38.6%).
Clinical Outcomes
Procedural complications and new transient or persis-
tent neurological deficits occurred in 9.8% and 7.6% of 
patients undergoing treatment, respectively (Table 3). Ar-
terial infarction occurred in 1 patient (0.5%) undergoing 
resection with preoperative embolization. The infarct oc-
curred in a patient with an unruptured SM grade IV cer-
ebellar AVM initially deemed inoperable but later treated 
after thrombosis of its venous outflow and onset of clinical 
symptoms resulting in severe brainstem edema. There was 
a single treatment-related death (0.5%), which was due to 
a delayed rehemorrhage in a patient with a ruptured SM 
grade IV AVM in the motor strip treated with 2 sessions 
of SRS.
The mean clinical follow-up for the cohort was 4.1 ± 
4.6 years (ruptured, 4.5 ± 4.9 years; and unruptured, 3.6 ± 
1.1 years). For patients with ruptured AVMs, a good neu-
rological outcome (mRS score ≤ 2) was obtained in 81.5% 
of patients at last follow-up (Table 4), and 115 patients 
(96.6%) neurologically improved or remained unchanged 
following treatment. For patients with unruptured AVMs, 
a good neurological outcome was obtained in 82.9% of 
patients at last follow-up (Table 4), and 59 patients (84.3%) 
neurologically improved or remained unchanged follow-
ing treatment. There were no deaths in the cohort of un-
ruptured AVMs.
Radiographic Obliteration
Obliteration rates by treatment modality are summa-
rized in Table 5. With treatment, complete obliteration for 
ruptured and unruptured AVMs was seen in 86 (73.5%) 
and 36 (54.5%) patients, respectively (complete oblitera-
tion rate, 66.7%). Spontaneous obliteration was not ob-
served in any AVM managed with observation. Complete 
obliteration was associated with lower SM grade (p < 0.01), 
lower combined SM and Supp-SM score (p < 0.01), hem-
orrhagic presentation (p < 0.01), treatment with surgery (p 
< 0.01), and AVM location (p = 0.04). Incomplete oblitera-
tion was associated with treatment with SRS (p < 0.01). 
Complete obliteration was seen in 35 (92.1%), 27 (67.5%), 
40 (64.5%), 21 (52.5%), and 1 (11.1%) patients with SM 
grade I, II, III, IV, and V lesions undergoing treatment, re-
spectively. Four recurrences were observed, with a median 
latency of detection of 3.6 years (range 1.8–16.8 years) and 
were subsequently treated with resection. All recurrences 
occurred after resection with or without preoperative em-
bolization. Three of the 4 recurrences were identified on 
delayed surveillance imaging, and the remaining recur-
rence was the result of hemorrhage.
Posttreatment Hemorrhage
Across the entire cohort, the rate of posttreatment hem-
orrhage was 0.02 events per person-year following initia-
tion of treatment. For ruptured AVMs, annual rates of 
rebleeding were 0.012 and 0.024 events per person-year, 
with median latencies of bleeding of 14.8 years (range 
12.8–16.8 years) and 2.1 years (range 0.85–18.7 years) 
for resection and SRS, respectively. Posttreatment hem-
orrhage occurred as result of 1 residual AVM and 1 re-
currence following resection. For unruptured AVMs, no 
bleeding events were observed after resection or emboli-
zation. Annual rates of bleeding were 0.01 and 0.04 events 
TABLE 2. Single- and multitreatment modalities of pediatric brain AVMs
Treatment Ruptured (n = 119) Unruptured (n = 70) Total (n = 189) p Value*
Single modality
 Resection 51 (42.9) 18 (25.7) 69 (36.5) 0.03
 Embolization 2 (1.7) 3 (4.3) 5 (2.6) 0.54
 SRS 29 (24.4) 27 (38.6) 56 (29.6) 0.06
 Observation 2 (1.7) 4 (5.7) 6 (3.2) 0.27
Multiple modalities
 Embolization + resection 15 (12.6) 12 (17.1) 27 (14.3) 0.52
 Volume-staged SRS + resection 7 (5.9) 5 (7.1) 12 (6.3) 0.97
 Resection + SRS 8 (6.7) 1 (1.4) 9 (4.8) 0.19
 Embolization + SRS 2 (1.7) 0 (0) 2 (1.1) 0.72
 Embolization + resection + SRS 3 (2.5) 0 (0) 3 (1.6) 0.46
Values are presented as number (%). Boldface type indicates statistical significance.
* Comparison between ruptured and unruptured aneurysms.
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per person-year for SRS and observation, respectively. 
Rates of posttreatment hemorrhage by modality and AVM 
SM grade are summarized in Table 6.
Discussion
Here, we report our 20-year institutional series describ-
ing our multidisciplinary approach and outcomes with 
treatment of pediatric brain AVMs. To our knowledge, this 
represents the largest clinical series describing treatment 
of pediatric AVMs across multiple treatment modalities. 
Multiple prior reports have focused on a sole treatment en-
tity, such as resection,3,5–7 embolization,8,9 or SRS.10–12 We 
have previously described our institutional series with re-
section and SRS.7,11 However, there is an inherent selection 
bias when describing a single treatment entity, and multi-
disciplinary approaches have been comparatively less fre-
quently reported.3,6, 15,16
The treatment of AVMs, especially when unruptured or 
high grade, remains controversial. Randomized controlled 
trials and prospective registries, such as ARUBA and 
SAIVM, have cast doubt as to whether treatment-related 
morbidity may exceed the risks of rupture with observa-
tion in a majority of AVMs.13,14 However, pediatric patients 
were not included in these studies. More recently, others 
reported acceptable safety profiles when treating ARUBA-
eligible patients,21 and, with longer follow-up, the associa-
tion of improved outcomes with conservative management 
compared with intervention remains unknown.13,22
Annual rates of rupture from brain AVMs are esti-
mated to be approximately 2%–4% per year overall.14,23–28 
With high-risk features, such as deep anatomic location, 
deep venous drainage, venous outflow stenosis, prior hem-
orrhage or microhemorrhage, or the presence of associated 
aneurysms, the annual risk of rupture may exceed 30%.27,29 
Therefore, a uniform approach applied to all AVMs equal-
ly is unlikely to yield optimal patient outcomes, and care-
TABLE 3. Procedural complications associated with resection, SRS, and endovascular 
embolization in pediatric brain AVMs
SM Grade
Ruptured AVMs Unruptured AVMs
No. of Patients (%) Complications (%) No. of Patients (%) Complications (%)
Resection (n = 120)
 I 24 (28.6) 0 10 (27.8) 0
 II 19 (22.6) 1 8 (22.2) 0
 III 24 (28.6 3 14 (39.0) 1
 IV 16 (19) 4 3 (8.33) 1
 V 0 (0) 0 1 (2.8) 0
 Total 84 8 (9.5) 36 2 (5.55)
SRS (n = 82)
 I 5 (10.2) 0 2 (6.1) 0
 II 5 (10.2) 0 8 (24.2) 0
 III 23 (46.9) 0 9 (27.3) 0
 IV 14 (28.6) 1 10 (30.3) 1
 V 2 (4.1) 0 4 (12.1) 0
 Total 49 1 (2.04) 33 1 (3.03)
Embolization (n = 36)
 I 3 (13.6) 2 1 (7.1) 0
 II 6 (27.3) 0 2 (14.3) 1 
 III 8 (36.4) 0 9 (64.3) 2 
 IV 5 (22.7) 0 2 (14.3) 1
 V 0 (0) 0 0 (0) 0
 Total 22 2 (9.1) 14 4 (28.6)
TABLE 4. Neurological outcome following treatment in pediatric 
brain AVMs 
mRS Score
Ruptured Unruptured 
Preop Postop Preop Postop
 0 0 (0) 29 (24.8) 2 (3.0) 21 (31.8)
 1 38 (32.5) 49 (41.9) 34 (51.5) 24 (36.4)
 2 19 (16.2) 17 (14.5) 18 (27.3) 11 (16.7)
 3 17 (14.5) 13 (11.1) 7 (10.6) 6  (9.1)
 4 17 (14.5) 6 (5.1) 5 (7.6) 2 (3.0)
 5 26 (22.2) 2 (1.7) 0 (0) 2 (3.0)
 6 0 (0) 1 (0.8) 0 (0) 0 (0)
Improved 81 (69.2) 29 (43.9)
Unchanged 32 (27.4) 27 (40.9)
Worse 4 (3.4) 10 (15.2)
Values are presented as number (%).
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ful patient selection is of paramount importance. With 
long life expectancy, pediatric patients with unruptured 
AVMs have a greater cumulative lifetime rupture risk than 
adults diagnosed with an unruptured AVM.26 The risk of 
brain hemorrhage has been shown to increase with each 
decade of life.25 Others have confirmed that advancing age 
is an independent predictor of rupture,27,30,31 and the inci-
dence of hemorrhage in untreated AVMs may be as high 
as 21% and 40% by the time the patient reaches the 4th 
and 7th decades of life, respectively.30 In addition, several 
high-risk angiogenic features, such as venous ectasia or 
associated aneurysms, are less common in children, sug-
gesting that they take time to develop and may increase 
hemorrhagic risk with increased age.32
For these reasons, we favor intervention for unruptured 
AVMs in children with a more aggressive approach for 
those whose aneurysms have ruptured (summarized in 
Fig. 1). All patients undergo MRI and DSA for treatment 
planning, and each case is reviewed during an interdisci-
plinary conference that includes pediatric neurosurgeons, 
cerebrovascular neurosurgeons, pediatric vascular neurol-
ogists, neurointerventional radiologists, and radiation on-
cologists. The interdisciplinary nature of this conference 
allows a discussion of a broad set of options and facilitates 
an appropriate treatment recommendation on a case-by-
case basis, particularly when multimodality therapy is 
considered. In addition, we always include the views of the 
family, the patient, and primary pediatricians to provide a 
holistic and comprehensive treatment plan.
Surgical Treatment
Low-grade AVMs are generally treated with resection, 
since this option has the highest likelihood of achieving 
obliteration by radiographic critera.7,33 We have previous-
ly reported that pediatric patients are more resilient and 
have better outcomes with AVM resection than do adults.7 
Nevertheless, proper patient selection is essential. Our 
decision-making is guided by considering both the SM 
and Supp-SM grading schemes and the patient’s clinical 
status.17,18 Resection is chosen more frequently in patients 
who present after AVM hemorrhage, and the presence of a 
hematoma often facilitates surgical access while minimiz-
ing transgression of normal brain and further morbidity.
For all surgical candidates, a preoperative stereotactic 
neuronavigational MRI with diffusion tensor tractogra-
phy facilitates planning of surgical corridors that avoid 
eloquent neural regions or tracts. Preoperative DSA is a 
prerequisite to understand flow dynamics and the angio-
architecture of the AVM nidus. Details regarding arterial 
inflow, venous drainage, and identification of high-risk 
TABLE 5. Rates of complete obliteration of brain AVMs following treatment
Treatment Ruptured (n = 119) Unruptured (n = 70) Total (n = 189)
Single modality
 Resection 48/51 (94.1) 17/18 (94.4) 65/69 (94.2)
 Embolization 1/2 (50) 0/3 (0) 1/5 (20)
 Radiosurgery 9/29 (31) 4/27 (14.8) 13/56 (23.2)
 Observation 0/2 (0) 0/4 (0) 0/6 (0)
Multiple modalities
 Embolization + resection 15/15 (100) 10/12 (83.3) 25/27 (92.6)
 Volume-staged SRS + resection 4/7 (57.1) 4/5 (80) 8/12 (66.7)
 Resection + SRS 5/8 (62.5) 1/1 (100) 6/9 (66.7)
 Embolization + SRS 2/2 (100) NA 2/2 (100)
 Embolization + resection + SRS 2/3 (66.7) NA 2/3 (66.7)
Values are presented as number per total applicable (%).
NA = not applicable (no patients in this subgroup).
TABLE 6. Rates of posttreatment hemorrhage in pediatric brain 
AVMs (events per year)
Treatment
Events per Yr
Ruptured Unruptured Total
Single modality
 Resection 0.012 0 0.009
 Embolization 0 0 0*
 Radiosurgery 0.024 0.010 0.019
 Observation 0† 0.041 0.039
Multiple modalities
 Embolization + resection 0 0 0
 Volume-staged SRS + resection 0.046 0.027 0.040
 Resection + SRS 0.022 0‡ 0.019
 Embolization + SRS 0.149§ NA 0.149§
 Embolization + resection + SRS 0.062 NA 0.062
SM grade
 I 0.020 0 0.014
 II 0 0.034 0.012
 III 0.020 0.014 0.018
 IV 0.020 0 0.014
 V 0.114 0.025 0.060
* Limited to 5 patients and 18 years of follow-up.
† Limited to 2 patients and 1.5 years of follow-up.
‡ Limited to 1 patient and 7.5 years of follow-up. 
§ Limited to 2 patients and 6.7 years of follow-up. 
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features such as intranidal aneurysms are only possible 
through high-quality DSA.
A patient who presents with an acute hemorrhage may 
be clinically unstable and unable to tolerate a complete 
treatment evaluation. In patients with either impending 
brain herniation or poorly controlled intracranial hyper-
tension, an immediate decompressive hemicraniectomy 
with or without clot evacuation is often required. After a 
recovery period (mean 18.6 ± 6.8 days), patients should 
undergo necessary diagnostic imaging prior to resection. 
Although there is a theoretical risk of rebleeding during 
this period, we did not observe any events during this 
acute period. This is consistent with prior reports in adult 
patients.34 We favor definitive treatment during the same 
hospital admission and find that 1–3 weeks is sufficient 
time for resolution of brain edema for most patients. In 
addition, this reduces stress associated with delayed inter-
vention in children. We do also utilize standard measures 
to manage diffuse brain swelling, such as decompressive 
hemicraniectomy, CSF drainage, and aggressive intracra-
nial pressure management.
Our surgical approach is extensively described else-
where for different AVM locations and subtypes.19 We 
have found it helpful to opt for a team-based approach in 
which a pediatric neurosurgeon and adult cerebrovascular 
surgeon operate together to maximize outcomes and mini-
mize morbidity. As incomplete resection is associated with 
higher posttreatment rupture risk,3 we favored complete 
resection when possible. The absence of residual shunting 
is confirmed by postoperative DSA during the same hos-
pitalization. Should this reveal residual shunting, several 
factors are considered: 1) how well the patient tolerated 
the first surgery; 2) whether the residual is in eloquent or 
noneloquent brain; and 3) the family’s opinion of further 
treatment. In scenarios in which the patient tolerated the 
surgery well, the residual is in noneloquent brain, and the 
family agrees, repeat resection during the same hospitaliza-
tion is recommended. If the patient poorly tolerated the ini-
tial surgery, the residual is in eloquent brain or was deemed 
too high risk intraoperatively, or the family is opposed to 
further invasive therapy, radiosurgery is recommended.
Stereotactic Radiosurgery
For AVMs in deep, eloquent, or surgically inaccessible 
structures, we favor SRS. As previously reported, we uti-
lize a prescription marginal dose of ≥ 18 Gy to maximize 
AVM obliteration while minimizing deleterious conse-
quences, such as symptomatic radiation-induced changes.11 
As a solitary treatment modality, we achieved obliteration 
in 23.2% of cases with SRS. Roughly one-third of the pa-
tients are within 3 years of treatment and may progress to 
complete obliteration in the years that follow, as supported 
by multiple studies.10–12, 35,36 When only those with ≥ 3 years 
of follow-up are considered, obliteration rates reach 47.6% 
with SRS. Others have advocated for a marginal dose of ≥ 
20 or 22 Gy, which has corresponded to obliteration rates of 
71.3% and 63% in independent clinical series, respective-
ly.12,35 However, lower obliteration rates with higher mar-
ginal doses have also been reported with pediatric AVMs.36
Our institutional bias favors resection for AVMs with 
lower SM–grade lesions, with SRS primarily used for 
higher-grade lesions and those in deeper locations. In gen-
eral, radiosurgical treatment of lower-grade AVMs is asso-
ciated with lower obliteration rates.10 In addition, increased 
radiation-induced changes are associated with higher mar-
ginal doses,37 and a greater incidence of symptomatic ra-
diation-induced changes is reported for deep AVMs, most 
notably in the brainstem or thalamus.37,38 Given our biases 
in patient selection, we therefore opt for a more conserva-
tive approach with respect to prescribed marginal doses, 
and our reported rehemorrhage rate (annual rate: 0.01 
events per person-year) and rate of symptomatic radiation-
induced changes (single patient, 1.2%) are in the lower 
range of reported values.3,10, 12, 15, 37,38
For AVMs with treatment volumes exceeding 8–10 
cm3, we used volume-staged SRS, with roughly 8–10 cm3 
treated per stage at 3- to 6-month intervals, with the first 
session targeted closest to the predominate arterial in-
flow.11,39 In the ruptured setting, treatment was initiated 
with a median latency from initial presentation of 122.5 
days. MRI/MRA was performed annually, and DSA was 
performed at 36 months. Multidisciplinary reevaluation 
was then performed to assess candidacy for further thera-
py. Resection was offered for AVMs that were appropriate-
ly downgraded (median latency for resection: 4.0 years), 
and this approach successfully led to complete obliteration 
in 8 of 12 AVMs (66.7%) treated with this paradigm. For 
AVMs that remained not amenable to surgery, additional 
salvage SRS was considered.
Endovascular Embolization
Advances in technology and device development have 
led to safe application of multiple endovascular emboli-
zation techniques in pediatric patients, including the use 
of NBCA, Onyx, particles, or detachable coils.8,40 Em-
bolization may be curative in select patients but requires 
complete nidus obliteration and can be associated with 
higher morbidity.41,42 Partial embolization of the nidus as 
sole therapy, however, is not a good treatment option and 
increases the risk of posttreatment AVM rupture in pedi-
atric patients.3,43 We therefore use embolization nearly ex-
clusively as an adjunct to facilitate either resection and/or 
SRS. When performed prior to surgery, one goal is preop-
erative flow reduction to minimize blood loss. Our focus is 
to occlude arterial inflow rather than achieve nidal oblit-
eration, and this often is accomplished with superselec-
tive microcatheterization of the feeding artery and either 
NBCA glue or Onyx. To minimize morbidity, we often re-
serve endovascular embolization for arterial pedicles that 
will be deep in the resection cavity and not immediately 
accessible to the surgeon.
A second use of endovascular embolization is to oc-
clude angiographic features at high risk of bleeding, such 
as flow-related or intranidal aneurysms.41 This is often ac-
complished with NBCA glue, Onyx, or detachable coils 
depending on the accessibility, size, and morphology of 
the aneurysm.41 Our approach is also tailored on the ba-
sis of subsequent planned treatment modalities. For sur-
gery, only arterial aneurysms that are not accessible at 
time of surgery are treated, such as remote flow-related 
aneurysms. For SRS, intranidal and flow-related arterial 
aneurysms are treated to prevent potential rupture dur-
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ing the latency period for the SRS to take effect. In select 
cases, we will embolize large, fistulous connections within 
AVMs treated with SRS, as these large connections tend 
not to respond to radiation. Embolization to reduce nidal 
size in preparation for SRS is typically not performed due 
to higher rates of hemorrhage and lower rates of AVM 
obliteration with tandem therapy.3,43,44
Application in High-Grade AVMs
Prior reports have discussed the challenges of applying 
other treatment algorithms in treating high-grade AVMs 
in pediatric patients,3,6, 15, 43,45 and applications of multiple 
treatment modalities may lead to additive treatment-re-
lated morbidity. The presented series comprised 49 high-
grade (SM grade IV and V) pediatric AVMs. Of those that 
were treated (n = 44), we report a complete obliteration 
rate of 45.5% (SM grade IV, 50.0%; SM grade V, 16.7%). 
This rate is higher than that in previously published re-
ports with multimodality therapy (range 22%–36%).6,15,45 
In most clinical series, high-grade AVMs account for the 
majority of rebleeding events, and, importantly, our im-
proved obliteration rate coincides with a lower proportion 
of high-grade AVMs with rebleeding (13.5%) when com-
pared with other published reports.15,43 In some clinical se-
ries, higher-grade AVMs account for all rebleeding events 
after treatment in long-term follow-up.43 In our series, re-
bleeding in high-grade AVMs accounted for 50% of all 
posttreatment rebleeding events.
As with other published studies,3,6, 15, 43,45 treatment of 
high-grade AVMs was associated with higher neurologi-
cal morbidity. The sole arterial infarction and death were 
confined to SM grade IV AVMs. Our complication rate 
for higher-grade AVMs (grades IV and V) was 16.3%, 
which is lower than that in other published studies (range 
23%–78%),6,15 and a favorable outcome was achieved in 
67.3%, in line with published reports (range 35%–69%).3,15, 
43,45 Prior reports have described much higher utilization of 
multiple modality therapy (reported range 62%–82%). We 
were more judicious in utilization of multiple treatment 
modalities, and only utilized multiple treatment modalities 
in 12 of 49 (24.5%) patients. These data support that more 
conservative utilization of multiple treatment modalities in 
a single patient may be associated with lower morbidity 
without compromising rates of obliteration. Whether dif-
ferences in patient populations, AVM angioarchitecture, 
and/or clinical follow-up also contributed to these differ-
ences when making comparisons between centers remains 
unknown and warrants further investigation through mul-
ticenter studies.
Limitations
The present study is a retrospective analysis of a single, 
high-volume treatment center. The purpose of this study 
was not to evaluate comparative efficacy and/or outcome 
of different treatment modalities, including resection, 
SRS, or endovascular embolization. Rather, the purpose 
was to provide a comprehensive experience of clinical care 
across a spectrum of brain AVMs at a high-volume pe-
diatric center. Treatment allocation was not randomized, 
and selection bias likely impacts comparability between 
different treatment modalities.
Conclusions
Coordinated multidisciplinary evaluation at high-vol-
ume centers permits case-by-case tailoring of treatment 
planning for safe and effective pediatric AVM care, in-
cluding treatment of a majority of high-grade AVMs. Em-
phasis should be first placed on identifying the optimal 
sole modality treatment given angiographic features and 
clinical presentation, including resection, SRS, or targeted 
endovascular embolization. Judicious use of multimodal-
ity therapy should be limited to appropriately selected pa-
tients after thorough team-based discussions to avoid ad-
ditive morbidity. Future multicenter studies are required to 
better design predictive models to aid with patient selec-
tion for multimodal pediatric care, especially with high-
grade AVMs.
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